Genky DrugStores Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 2 analysts
Updated 2026/08/01Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥7 | -50.0% |
| 2025 | ¥13 | 0.0% |
| 2024 | ¥13 | +4.0% |
| 2023 | ¥13 | 0.0% |
| 2022 | ¥13 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥154,639M | ¥169,059M | ¥184,860M | ¥200,786M |
| Gross Profit | ¥30,954M | ¥34,553M | ¥37,620M | ¥40,889M |
| Operating Income | ¥5,675M | ¥6,709M | ¥9,015M | ¥9,658M |
| Pretax Income | ¥6,142M | ¥6,774M | ¥8,906M | ¥10,118M |
| Net Income | ¥4,420M | ¥4,764M | ¥6,324M | ¥7,066M |
| EPS | ¥145.44 | ¥156.79 | ¥207.94 | ¥232.04 |
| Operating Margin | 3.67% | 3.97% | 4.88% | 4.81% |
| Balance Sheet | ||||
| Total Assets | ¥97,118M | ¥105,912M | ¥113,939M | ¥127,326M |
| Total Equity | ¥36,232M | ¥40,680M | ¥46,679M | ¥53,427M |
| Total Liabilities | ¥60,886M | ¥65,232M | ¥67,260M | ¥73,899M |
| Cash | ¥5,438M | ¥5,329M | ¥5,896M | ¥6,221M |
| Interest-bearing Debt | ¥30,959M | ¥32,354M | ¥30,648M | ¥34,374M |
| Equity Ratio | 37.31% | 38.41% | 40.97% | 41.96% |
| D/E Ratio | 0.85 | 0.80 | 0.66 | 0.64 |
| Cash Flow | ||||
| Operating CF | ¥6,076M | ¥8,773M | ¥13,256M | ¥12,597M |
| Investing CF | -¥10,588M | -¥9,736M | -¥10,631M | -¥15,618M |
| Financing CF | ¥2,037M | ¥854M | -¥2,058M | ¥3,346M |
| Free CF | -¥4,430M | -¥1,155M | ¥2,815M | -¥2,510M |
| Efficiency | ||||
| ROE | 12.20% | 11.71% | 13.55% | 13.23% |
| ROA | 4.55% | 4.50% | 5.55% | 5.55% |
Latest IR Information
-
Notice on Granted Stock Options (Stock Acquisition Rights)
The board resolved to grant stock acquisition rights under particularly favorable terms to internal directors, employees, and directors/employees of subsidiaries. The total grant cap is 1,500 rights, with 100 shares per right, and the issuance date is assumed to be...
Read more -
2026 Fiscal Year Supplementary Financial Data | Sales of approximately 244 billion yen (YoY +10.6%)
Genky DrugStores' FY2026 first-half financial supplement shows achieved sales of approximately 244 billion yen (YoY +10.6%), with store count also expanding. The company continues to pursue aggressive store expansion and revenue growth.
Read more -
[Genky DrugStores] FY2025 Performance Trends and Store Strategy | July 2026
Genky DrugStores reports the trends in FY2025 sales, same-store sales, and customer visits, along with updates on store expansions, renovations, and closures. The company continues its store strategy into FY2026, closely monitoring sales and customer traffic movements.
Read more -
Genky FY2026 June Financial Summary｜Sales ¥220.6 billion (YoY +9.9%)
Genky announced its financial results for the fiscal year ending June 2026, with sales of ¥220.6 billion (YoY +9.9%), operating income of ¥109.5 billion (YoY +8.4%), and net income of ¥70.8 billion (YoY +11.4%), achieving increases in both revenue and...
Read more -
Genki Drug Stores June 2026 Fiscal Year Earnings Report ｜ Sales of 220.9 billion yen (+10.6% YoY)
Genki Drug Stores achieved sales of 220.9 billion yen (up 10.6% YoY) for the fiscal year ending June 2026, maintaining increased revenue and profit. The company plans to continue proactive store expansion and operational efficiencies.
Read more
Latest News (5 items)
-
Average Analyst Rating: strong_buy
Average Target Price: ¥5,100
Rating Score: 1.00 (Based on 2 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Genky DrugStores Co., Ltd. engages in the management and operation of food and drug chain stores in Japan. Genky DrugStores Co., Ltd. was founded in 1988 and is headquartered in Sakai, Japan.
